344 related articles for article (PubMed ID: 20035611)
1. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
Mueller EW; Boucher BA
Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
Bland CM; Pai MP; Lodise TP
Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological considerations for the proper clinical use of aminoglycosides.
Pagkalis S; Mantadakis E; Mavros MN; Ammari C; Falagas ME
Drugs; 2011 Dec; 71(17):2277-94. PubMed ID: 22085385
[TBL] [Abstract][Full Text] [Related]
4. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
5. Suboptimal aminoglycoside dosing in critically ill patients.
Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
[TBL] [Abstract][Full Text] [Related]
6. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation.
Peris-Marti JF; Borras-Blasco J; Rosique-Robles JD; Gonzalez-Delgado M
J Clin Pharm Ther; 2004 Feb; 29(1):65-70. PubMed ID: 14748900
[TBL] [Abstract][Full Text] [Related]
8. Optimizing use of aminoglycosides in the critically ill.
Rea RS; Capitano B
Semin Respir Crit Care Med; 2007 Dec; 28(6):596-603. PubMed ID: 18095223
[TBL] [Abstract][Full Text] [Related]
9. Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration.
Chuk AC; Saeed F; Kousar N; Burrill S; Barns B; Rickrode G; Fu J; Katrych O; Saunders-Hao P; Block C; Lahey T
Clin Nephrol; 2015 Oct; 84(4):214-21. PubMed ID: 26308080
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of four once-daily aminoglycoside dosing nomograms.
Wallace AW; Jones M; Bertino JS
Pharmacotherapy; 2002 Sep; 22(9):1077-83. PubMed ID: 12222541
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update.
Hoff BM; Maker JH; Dager WE; Heintz BH
Ann Pharmacother; 2020 Jan; 54(1):43-55. PubMed ID: 31342772
[No Abstract] [Full Text] [Related]
12. Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients.
Mann HJ; Wittbrodt ET; Baghaie AA; Cerra FB
Pharmacotherapy; 1998; 18(2):371-8. PubMed ID: 9545157
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
[TBL] [Abstract][Full Text] [Related]
14. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
Dager WE; King JH
Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
[TBL] [Abstract][Full Text] [Related]
16. Aminoglycoside dosing considerations in intensive care unit patients.
Watling SM; Dasta JF
Ann Pharmacother; 1993 Mar; 27(3):351-7. PubMed ID: 8267695
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.
Barletta JF; Johnson SB; Nix DE; Nix LC; Erstad BL
J Trauma; 2000 Nov; 49(5):869-72. PubMed ID: 11086778
[TBL] [Abstract][Full Text] [Related]
18. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?
Roberts JA; Paul SK; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
Clin Infect Dis; 2014 Apr; 58(8):1072-83. PubMed ID: 24429437
[TBL] [Abstract][Full Text] [Related]
19. Management of aminoglycosides in the intensive care unit.
Radigan EA; Gilchrist NA; Miller MA
J Intensive Care Med; 2010; 25(6):327-42. PubMed ID: 20837630
[TBL] [Abstract][Full Text] [Related]
20. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.
Kim MJ; Bertino JS; Erb TA; Jenkins PL; Nafziger AN
J Clin Pharmacol; 2004 Jul; 44(7):696-707. PubMed ID: 15199074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
